KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsLeila Noetzli, James D. McIninch, Frederic Tremblay, Mark K. Schlegel, Adam Castoreno
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., daRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disorder in a subject.
Claims35
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of ketohexokinase (KHK) in a cell, or a salt thereof, wherein the dsRNA comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises the nucleotide sequence 5′-CUACGGAGACGUGGUGUUUGU-3′ of SEQ ID NO:
- 89, and wherein the antisense strand comprises the nucleotide sequence 5′-ACAAACACCACGUCUCCGUAGCC-3′ of SEQ ID NO:
- 313.
2-15. (canceled)
18-21. (canceled)
23-26. (canceled)
28-33. (canceled)
42-62. (canceled)
65-69. (canceled)
71-82. (canceled)
87-92. (canceled)
94-97. (canceled)
99-103. (canceled)
106-108. (canceled)
Dependencies are inferred from the claim text.